REGENXBIO Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsREGENXBIO is a clinical-stage gene therapy company developing one-time AAV-based treatments for retinal diseases, Duchenne muscular dystrophy, and lysosomal storage disorders, with its lead program sura-vec partnered with AbbVie.
What they do
REGENXBIO uses its proprietary NAV Technology Platform (AAV vectors) to develop investigational gene therapies that deliver functional genes to address genetic defects. Its lead programs include sura-vec (ABBV-RGX-314) for wet age-related macular degeneration and diabetic retinopathy in collaboration with AbbVie, RGX-202 for Duchenne muscular dystrophy, and RGX-121 for Hunter syndrome. The company is clinical-stage with no approved products, generating revenue primarily from collaboration milestones and license fees.
Revenue drivers
- AbbVie collaboration (sura-vec/ABBV-RGX-314) — Primary revenue source: includes a $100 million milestone from AbbVie for first patient dosing in NAAVIGATE in Q2 2026, with revenue of $108.0M in Q2 2026 largely from this event.
- Other collaboration and license agreements — Historically contributed to annual revenue: 2021 revenue of $470.3M included large upfronts, but 2022-2024 revenue declined to $90-113M as those deals wound down.
- Grant and other revenue — Minor contribution; not separately disclosed in provided excerpts.
Recent performance
In Q2 2026, REGENXBIO reported revenue of $108.0M, driven primarily by the $100M milestone from AbbVie for NAAVIGATE dosing. For full-year 2025, revenue was $170.4M and net loss was -$193.9M, improved from -$227.1M in 2024. Operating cash flow was -$124.0M in 2025, continuing a trend of negative cash flows. As of June 30, 2026, cash and equivalents were $36.5M, but the company raised over $200M in July 2026, with pro forma cash in excess of $310M.
Strategy
REGENXBIO is focused on advancing its lead programs to regulatory approval: sura-vec pivotal data in wet AMD expected Q4 2026 with global submissions in 2027, RGX-202 BLA initiation in Q3 2026 under accelerated approval, and RGX-121 BLA resubmission in Q3 2026. The company is scaling in-house manufacturing capability (Manufacturing Innovation Center) for RGX-202 commercial supply. It is using capital from milestone payments and equity offerings to extend cash runway into Q4 2027, supporting planned ex-U.S. trials (AFFINITY RISE) and other pipeline investments.
Risks
- Clinical and regulatory delays — FDA clinical holds on RGX-111 and RGX-121 could delay or terminate those programs, and the RGX-121 BLA received a Complete Response Letter, with uncertain resubmission outcome.
- Dependence on lead candidates — Substantially dependent on success of sura-vec, RGX-202, and RGX-121; failure of pivotal trials would materially harm the business.
- Cash burn and dilution — Consistent negative cash flows (operating cash flow -$124.0M in 2025) and reliance on external capital; recent equity offering and milestone payments extend runway but future dilution or financing risk remains.
- Competitive and reimbursement risk — Gene therapy candidates face competition from existing anti-VEGF therapies (e.g., ranibizumab, aflibercept) for wet AMD and DR, and from other gene therapies; commercial success may be limited by pricing and reimbursement hurdles.
Outlook
Management expects to report topline data from the sura-vec pivotal trials (ATMOSPHERE and ASCENT) in Q4 2026, followed by global regulatory submissions in 2027. The RGX-202 BLA submission is planned to initiate in Q3 2026, with potential accelerated approval in 2H 2027. The company also plans to resubmit the RGX-121 BLA in Q3 2026 and initiate the AFFINITY RISE ex-U.S. trial in 1H 2027. With over $310M pro forma cash, management expects to fund operations into Q4 2027.